Hepatology

Semaglutide 2.4 mg/week reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits.

New European research reveals that remission in autoimmune hepatitis does not guarantee recovery, with many patients reporting fatigue and poor quality of life.

Mazdutide, a dual GLP-1 and glucagon receptor agonist, significantly reduced liver fat and improved metabolic markers in people with MASLD and obesity.

New research found early Alzheimer’s markers in rats with liver dysfunction, suggesting liver health may play a key role in dementia risk.

Recent research has examined the dual benefits of dietary patterns that improve MASLD outcomes while reducing environmental impact.

Elevated serum tyrosine predicts HCC and mortality in chronic liver disease, helping identify high-risk patients for closer monitoring.

Interestingly, the timing of vaccination, often initiated within 12 months post-transplant, did not significantly influence antibody development.

While the control group demonstrated no notable change, the intervention group showed a clear improvement in knowledge immediately after completing the VR module.